VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
VALANX Biotech has raised $3.5M in total funding. The most recent round was Series Unknown. The last funding was announced in March 2026.
VALANX Biotech's investors include SOSV, Fujifilm, XISTA Science Ventures, austria Wirtschaftsservice (aws), tecnet equity.
VALANX Biotech is headquartered in Graz, Austria.
VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
VALANX Biotech is at the Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VALANX Biotech — Funding & Investors." VCBacked, March 12, 2026, https://www.vcbacked.co/company/valanx-biotech. Accessed July 19, 2026.
VCBacked. (2026). VALANX Biotech — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/valanx-biotech
{{cite web |title=VALANX Biotech — Funding & Investors |url=https://www.vcbacked.co/company/valanx-biotech |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated